Literature DB >> 25736276

The role of screening and monitoring for bleomycin pulmonary toxicity.

Brittney M Shippee1, Jill S Bates2, Kristy L Richards3.   

Abstract

Bleomycin-induced pulmonary toxicity can have a significant impact on patient outcomes. However, no guidelines for ideal screening and monitoring are available. This paper reviews the literature to identify the best way to monitor and reduce patient risk for bleomycin pulmonary toxicity. We have created evidence-based guidelines to help healthcare professionals identify patient risk factors and provide appropriate assessment and monitoring for patients receiving bleomycin therapy.
© The Author(s) 2015.

Entities:  

Keywords:  Bleomycin; monitoring; pulmonary toxicity; risk factors

Mesh：

Substances：

Year:  2015        PMID： 25736276     DOI： 10.1177/1078155215574294

Source DB:  PubMed          Journal:  J Oncol Pharm Pract        ISSN： 1078-1552            Impact factor:   1.809


  9 in total

Review 1.  Anaesthesia for retroperitoneal lymph node dissection in the treatment of testicular cancer.

Authors:  M Stephens; T Murphy; D Hendry
Journal:  BJA Educ       Date:  2019-07-05

2.  Cause-Specific Mortality Following Initial Chemotherapy in a Population-Based Cohort of Patients With Classical Hodgkin Lymphoma, 2000-2016.

Authors:  Graça M Dores; Rochelle E Curtis; Nicole H Dalal; Martha S Linet; Lindsay M Morton
Journal:  J Clin Oncol       Date:  2020-09-18       Impact factor: 44.544

Review 3.  Testicular cancer survivorship: Long-term toxicity and management.

Authors:  Noa Shani Shrem; Lori Wood; Robert J Hamilton; Kopika Kuhathaas; Piotr Czaykowski; Matthew Roberts; Andrew Matthew; Jason P Izard; Peter Chung; Lucia Nappi; Jennifer Jones; Denis Soulières; Armen Aprikian; Nicholas Power; Christina Canil
Journal:  Can Urol Assoc J       Date:  2022-08       Impact factor: 2.052

4.  Real-world evidence of ABVD-like regimens compared with ABVD in classical Hodgkin lymphoma: a 10-year study from China.

Authors:  Qing Wen; Jingjing Ge; Yaxin Lei; Yue Zhang; Xiaoshuang Kong; Wenhua Wang; Huting Hou; Zeyuan Wang; Siyu Qian; Mengjie Ding; Meng Dong; Linan Zhu; Mingzhi Zhang; Xudong Zhang; Qingjiang Chen
Journal:  J Cancer Res Clin Oncol       Date:  2022-08-28       Impact factor: 4.322

5.  Death by bleomycin pulmonary toxicity in ovarian dysgerminoma with pathologic complete response to chemotherapy. A case report.

Authors:  Julia Calzas Rodríguez; María Del Carmen Juarez Morales; Miguel Angel Racionero Casero
Journal:  Respir Med Case Rep       Date:  2016-04-19

Review 6.  Marine Sponge Natural Products with Anticancer Potential: An Updated Review.

Authors:  Cinzia Calcabrini; Elena Catanzaro; Anupam Bishayee; Eleonora Turrini; Carmela Fimognari
Journal:  Mar Drugs       Date:  2017-10-13       Impact factor: 5.118

7.  Bleomycin-induced pulmonary toxicity and treatment with infliximab: A case report.

Authors:  Victor Ge; Iouri Banakh; Ravindranath Tiruvoipati; Kavi Haji
Journal:  Clin Case Rep       Date:  2018-09-04

Review 8.  Development of a best-practice clinical guideline for the use of bleomycin in the treatment of germ cell tumours in the UK.

Authors:  Robert A Watson; Hugo De La Peña; Maria T Tsakok; Johnson Joseph; Sara Stoneham; Jonathan Shamash; Johnathan Joffe; Danish Mazhar; Zoe Traill; Ling-Pei Ho; Sue Brand; Andrew S Protheroe
Journal:  Br J Cancer       Date:  2018-10-25       Impact factor: 7.640

9.  Bleomycin-Induced Cryptogenic Organizing Pneumonia Manifested as Spontaneous Pneumothorax in a Patient with Classic Seminoma.

Authors:  Diana Lizbeth Ortíz-Farías; Stephanie López-Romero; Hirian Alonso Moshe Barrera-Pérez; Gary Kosai Vargas-Mendoza; Arturo Cortes-Telles
Journal:  Tanaffos       Date:  2019-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.